



08-20-03

JP 1634

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	09/805,293	
	Filing Date	March 12, 2001	
	First Named Inventor	Halsted, Charles H.	
	Art Unit	1634	
	Examiner Name	Souaya, Jehanne E.	
Total Number of Pages in This Submission	4	Attorney Docket Number	023070-111710US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard; copy of references
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual	Townsend and Townsend and Crew LLP Laurence J. Hyman Reg. No. 35,551	
Signature		
Date	August (19), 2003	

CERTIFICATE OF MAILING		
Express Mail Label: EV 330856951 US		
I hereby certify that this correspondence is being deposited with the United States Postal Service with "Express Mail Post Office to Address" service under 37 CFR 1.10 on this date and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450		
Typed or printed name	Patricia Andrews	
Signature		Date August (19), 2003


This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

"Express Mail" Label No. EV 330856951 US  
Date of Deposit Aug. 19, 2003

PATENT  
Attorney Docket No.: 023070-111710US  
Client Reference No.: 2000-254-1

I hereby certify that this is being deposited with the United States Postal  
Service "Express Mail Post Office to Address" service under 37 CFR 1.10  
on the date indicated above and is addressed to:



Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

By: Patricia A. Anderson

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

HALSTED and DEVLIN

Application No.: 09/805,293

Filed: March 12, 2001

For: MUTATIONS IN HUMAN  
GLUTAMATE CARBOXYPEPTIDASE  
II GENE IMPACTING FOLATE  
METABOLISM, AND DETECTION OF  
AFFECTED INDIVIDUALS

Examiner: Souaya, Jehanne E.

Art Unit: 1634

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
CFR §1.97 and §1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

  
Laurence J. Hyman  
Reg. No. 35,551

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
MTD:mtd  
60020498 v1



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page

1

of

**Complete if Known**

Application Number

09/805,293

Filing Date

March 12, 2001

First Named Inventor

Halsted, Charles H., et. al.

Art Unit

1634

Examiner Name

Souaya, Jehanne E.

Attorney Docket Number

02307O-111710US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
6	AA /	Luthi-Carter et al., "Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase II", <i>PNAS</i> 95: 3215-3220 (1998).	
7	AB /	Clarke et al., "Folate, Vitamin B <sub>12</sub> and Serum Total Homocysteini Levels in Confirmed Alzheimer Disease", <i>Arch Neurol.</i> 55: 1449-1455 (1998).	
1	AC /	Devlin et al., "Molecular Studies of Human Intestinal Folylpoly-Glutamate Carboxypeptidase", <i>Gastroenterology</i> 116: A874 (1999).	
4	AD /	Israeli et al., "Molecular Cloning of a Complementary DNA Encoding a Prostate-specific Membrane Antigen", <i>Cancer Res.</i> 53: 227-230 (1993).	
6	AE /	Luthi-Carter et al., "Molecular Characterization of Human Brain N-Acetylated $\alpha$ -Linked Acidic Dipeptidase (NAALADase)", <i>J. Pharm. Exper. Therap.</i> 286: 1020-1025 (1998).	
15	AF /	O'Keefe et al., "Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene", <i>Biochim. Biophys. Acta</i> 1443: 113-127 (1998).	
6	AG /	Rawlings et al., "Structure of membrane glutamate carboxypeptidase", <i>Biochim. Biophys Acta</i> 1139: 247-252 (1997).	
3	AH /	Su et al., "Alternatively Spliced Variants of Prostate-specific Membrane Antigen RNA: Ratio of Expression as a Potential Measurement of Progression", <i>Cancer Res.</i> 55: 1441-1443 (1995).	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.  
60018295 v1